Alize Pharma III SAS raised €67m ($75m) in an oversubscribed Series A financing led by LSP, which was joined by other new backers Novo Ventures, Kurma Partners, Orbimed, Pontifax, Partners Innovation Fund, and Innobio 2 (managed by Bpifrance), and returning shareholders Sham Innovation Santé/Turenne Capital, Crédit Agricole Création, and TAB Consulting. The company will use the funds to move its two preclinical candidates into the clinic in 2020. AZP3601 is being developed for hypoparathyroidism, while AZP3404 is designed to treat syndromes of severe insulin resistance. Alize also plan to expand its team in France and open a subsidiary in Boston.
Chinook Therapeutics Inc., working on precision medicines for kidney diseases, raised $65m through its Series A round. Founding investor...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?